Author:
Rajbhandari Prabi,Goodrich Nathaniel,Nabower Aleisha M.,Brown Miraides F.,Ekambaram Maheswari,Eisenberg Jaclyn,Forbes Michael L.,Gollehon Nathan,Martin Kimberly C.,McCulloh Russell,Stone Bryan,Tandy Matt,Snowden Jessica
Abstract
Abstract
Background
The Meningitis/Encephalitis FilmArray® Panel (ME panel) was approved by the U.S. Food and Drug Administration in 2015 and provides rapid results when assessing patients with suspected meningitis or encephalitis. These patients are evaluated by various subspecialties including pediatric hospital medicine (PHM), pediatric emergency medicine (PEM), pediatric infectious diseases, and pediatric intensive care unit (PICU) physicians. The objective of this study was to evaluate the current use of the ME panel and describe the provider and subspecialty practice variation.
Methods
We conducted an online cross-sectional survey via the American Academy of Pediatrics Section of Hospital Medicine (AAP-SOHM) ListServe, Brown University PEM ListServe, and PICU Virtual pediatric system (VPS) Listserve.
Results
A total of 335 participants out of an estimated 6998 ListServe subscribers responded to the survey. 68% reported currently using the ME panel at their institutions. Among test users, most reported not having institutional guidelines on test indications (75%) or interpretation (76%). 58% of providers self-reported lack of knowledge of the test’s performance characteristics. Providers from institutions that have established guidelines reported higher knowledge compared to those that did not (51% vs. 38%; p = 0.01). More PHM providers reported awareness of ME panel performance characteristics compared to PEM physicians (48% vs. 27%; p = 0.004); confidence in test interpretation was similar between both groups (72 vs. 69%; p = 0.80).
Conclusion
Despite the widespread use of the ME panel, few providers report having institutional guidelines on test indications or interpretation. There is an opportunity to provide knowledge and guidance about the ME panel among various pediatric subspecialties.
Funder
Child Health Research Institute, University of Nebraska Medical Center
Publisher
Springer Science and Business Media LLC
Reference26 articles.
1. Bagdure D, Custer JW, Rao S, et al. Hospitalized Children With Encephalitis in the United States: A Pediatric Health Information System Database Study. Pediatr Neurol. 2016;61:58–62.
2. Balada-Llasat JM, Rosenthal N, Hasbun R, et al. Cost of managing meningitis and encephalitis among infants and children in the United States. Diagn Microbiol Infect Dis. 2019;93(4):349–54.
3. FDA allows marketing of the first nucleic acid-based test to detect multiple pathogens from a single sample of cerebrospinal fluid. October 8. 2015. https://www.infectioncontroltoday.com/fda/fda-allows-marketing-first-nucleic-acid-based-test-detect-multiple-pathogens-csf. Published 2015. Accessed 4/2/2020, 2020.
4. The BioFire FilmArray Meningitis/Encephalitis(ME) Panel. https://www.biofiredx.com/products/the-filmarray-panels/filmarrayme/. Accessed 3/31/2020, 2020.
5. O’Brien MP, Francis JR, Marr IM, Baird RW. Impact of Cerebrospinal Fluid Multiplex Assay on Diagnosis and Outcomes of Central Nervous System Infections in Children: A Before and After Cohort Study. Pediatr Infect Dis J. 2018;37(9):868–71.